Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.94
-0.03-1.52%
Pre-Market: 8:56 AM EDT
Comments
Loading...
Innate Pharma Analyst Ratings and Price Targets | NASDAQ:IPHA | Benzinga
Innate Pharma SA has a consensus price target of $10.83 based on the ratings of 3 analysts. The high is $12 issued by Citigroup on September 16, 2022. The low is $9 issued by SVB Leerink on November 15, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 28, 2025, February 6, 2025, and January 17, 2025, respectively. With an average price target of $11.5 between HC Wainwright & Co., there's an implied 492.78% upside for Innate Pharma SA from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
SVB Leerink
Citigroup
1calculated from analyst ratings
Analyst Ratings for Innate Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/28/2025 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 02/06/2025 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 01/17/2025 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 12/09/2024 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2024 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2024 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 03/22/2024 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11.5 → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2023 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 06/16/2023 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $11.5 | Reiterates | Buy → Buy | Get Alert |
| 03/24/2023 | Buy Now | 492.78% | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $11.5 | Reiterates | → Buy | Get Alert |
| 11/15/2022 | Buy Now | 363.92% | SVB Leerink | Daina Graybosch42% | $10 → $9 | Maintains | Outperform | Get Alert |
| 09/16/2022 | Buy Now | 518.56% | Citigroup | Yigal Nochomovitz54% | $16 → $12 | Maintains | Buy | Get Alert |
| 08/02/2022 | Buy Now | 415.46% | SVB Leerink | Daina Graybosch42% | $11 → $10 | Maintains | Outperform | Get Alert |
| 05/11/2022 | Buy Now | 467.01% | SVB Leerink | Daina Graybosch42% | $10 → $11 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Innate Pharma (IPHA) stock?
The latest price target for Innate Pharma (NASDAQ:IPHA) was reported by HC Wainwright & Co. on March 28, 2025. The analyst firm set a price target for $11.50 expecting IPHA to rise to within 12 months (a possible 492.78% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Innate Pharma (IPHA)?
The latest analyst rating for Innate Pharma (NASDAQ:IPHA) was provided by HC Wainwright & Co., and Innate Pharma reiterated their buy rating.
When was the last upgrade for Innate Pharma (IPHA)?
There is no last upgrade for Innate Pharma
When was the last downgrade for Innate Pharma (IPHA)?
There is no last downgrade for Innate Pharma.
When is the next analyst rating going to be posted or updated for Innate Pharma (IPHA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innate Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innate Pharma was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.
Is the Analyst Rating Innate Pharma (IPHA) correct?
While ratings are subjective and will change, the latest Innate Pharma (IPHA) rating was a reiterated with a price target of $11.50 to $11.50. The current price Innate Pharma (IPHA) is trading at is $1.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.